Drug Combination Details
| General Information of the Combination (ID: C11915) | |||||
|---|---|---|---|---|---|
| Name | Ursodeoxycholic acid NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Huh-BAT | Hepatocellular carcinoma | Homo sapiens | ||||
| Experimental
Result(s) |
Sorafenib and ursodeoxycholic combination is efficacious in treating hepatocellular carcinoma by inhibiting cell proliferation and inducing apoptosis through reactive oxygen species dependent activation of ERK and dephosphorylation of STAT3. | |||||
